Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer

KIZ OpenIR > 科研部门 > 肿瘤生物学（陈策实）

	Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
	Li, Zhen; Zou, Wei; Zhang, Ji; Zhang, Yunjiao; Xu, Qi; Li, Siyuan; Chen, Ceshi
	2020
发表期刊	FRONTIERS IN PHARMACOLOGY
ISSN	1663-9812
卷号	11
摘要	As a new-generation CDK inhibitor, a CDK4/6 inhibitor combined with endocrine therapy has been successful in the treatment of advanced estrogen receptor-positive (ER+) breast cancer. Although there has been overall progress in the treatment of cancer, drug resistance is an emerging cause for breast cancer-related death. Overcoming CDK4/6 resistance is an urgent problem. Overactivation of the cyclin-CDK-Rb axis related to uncontrolled cell proliferation is the main cause of CDK4/6 inhibitor resistance; however, the underlying mechanisms need to be clarified further. We review various resistance mechanisms of CDK4/6 inhibitors in luminal breast cancer. The cell signaling pathways involved in therapy resistance are divided into two groups: upstream response mechanisms and downstream bypass mechanisms. Finally, we discuss possible strategies to overcome CDK4/6 inhibitor resistance and identify novel resistance targets for future clinical application.
收录类别	sci
语种	英语
文献类型	期刊论文
条目标识符	http://ir.kiz.ac.cn/handle/152453/12879
专题	科研部门_肿瘤生物学（陈策实）
推荐引用方式 GB/T 7714	Li, Zhen,Zou, Wei,Zhang, Ji,et al. Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer[J]. FRONTIERS IN PHARMACOLOGY,2020,11.
APA	Li, Zhen.,Zou, Wei.,Zhang, Ji.,Zhang, Yunjiao.,Xu, Qi.,...&Chen, Ceshi.(2020).Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer.FRONTIERS IN PHARMACOLOGY,11.
MLA	Li, Zhen,et al."Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer".FRONTIERS IN PHARMACOLOGY 11(2020).

条目包含的文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
2021110106.pdf（882KB）	期刊论文	出版稿	开放获取	CC BY-NC-SA	请求全文